MLLCF (Molecular Partners AG) Change In Inventory: $0.00 Mil (TTM As of Mar. 2026)


MLLCF Molecular Partners AG MLLCF
25 GF Score
Price $3.60
GF Value $0.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Change In Inventory?

Molecular Partners AG MLLCF 25 Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Molecular Partners AG's change in inventory for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Molecular Partners AG's inventory stayed the same from Dec. 2025 to Mar. 2026 .

Molecular Partners AG's change in inventory for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Molecular Partners AG's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Molecular Partners AG's Total Inventories for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Molecular Partners AG  (OTCPK:MLLCF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Molecular Partners AG's Days Inventory for the quarter that ended in is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Molecular Partners AG's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Molecular Partners AG's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG Change In Inventory Related Terms


Molecular Partners AG Change In Inventory Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Change In Inventory Chart

Molecular Partners AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Molecular Partners AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MLLCF
25GF Score
Molecular Partners AG MLLCF
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $0.00 Mil mean?
Molecular Partners AG (MLLCF) has a Change In Inventory of $0.00 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Molecular Partners AG and its competitors.
Is Molecular Partners AG's Change In Inventory too high?
Molecular Partners AG's current Change In Inventory is $0.00 Mil. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Change In Inventory compare to VRTX and REGN?
Molecular Partners AG's Change In Inventory of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Molecular Partners AG and its competitors. Molecular Partners AG's current Change In Inventory is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current Change In Inventory is $0.00 Mil. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Change In Inventory is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

  • Change In Inventory: $0.00 Mil
  • GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score

Get the complete analysis for MLLCF

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.60
Price
$0.42
GF Value